Belgian Law Seeks To Tackle Drug Shortages
Limits Risk Of ‘Excessive’ Sanctions For Suppliers
Executive Summary
Belgium is to impose new reporting obligations on pharmaceutical companies that become aware of drug supply interruptions, in a move that is seen by suppliers as less draconian than measures taken in other European countries.
You may also be interested in...
Belgian Body Welcomes Clawback Exemption For Generics/Biosimilars Amid Price Cuts
Belgian body Medaxes is content with the latest pharmaceutical pricing legislation in the country, which cuts generics and biosimilars prices but also exempts such drugs from pharmaceutical clawback taxes.
Drug Shortage Crisis Worsens
As efforts continue to find ways of mitigating medicine shortages, a European survey has found not only that the situation is worsening, but that efforts to improve things are hindered by the patchwork of different rules on substitution and importation across the EU.
Belgium Launches Probe On Biosimilar Restrictions
Belgium’s competition regulator has announced that it is investigating practices that have restricted or prevented biosimilars from entering the market.